cancer

A study uncovers a novel connection between the biomolecule and cancer progression.

First, the genetically engineered cells became CD8⁺ killer T cells that wiped out his leukemia. Then they transformed into a stable population of CD4⁺ helper T cells that continue to circulate in his body.

When coated with positively charged particles, the bacteria shuttled antigens out of tumors and activated the immune system, a study finds.

Mintz’s experiments over her six-decade career were foundational to cancer and genetics research.

A study reveals a connection between the loss of enzymes responsible for removing methyl groups from DNA, nucleic acid knots, and cancer development in mice.

Several research groups have found that Toxoplasma gondii infection can ramp up antitumor immune responses in mice. Can the single-cell parasite be used to develop safe treatments for humans?

Lab studies link the oral bacteria Fusobacterium nucleatum to cancers from the gut to the head and neck. Could targeting the microbe tackle tumors?

This year revealed just how much scientists have learned about the disease, from how animals become naturally cancer-resistant to how tumor cells harness extracellular DNA to develop rapid drug resistance.

Researchers involved in an eight-year project to reproduce the findings of more than 50 high-impact papers struggled to get enough information to even carry out most of the experiments.

The mitochondria stolen via these tiny connections give tumor cells a metabolic boost while the T cells are left weakened, according to in vitro experiments.

The binding of histamine with one of its receptors within the tumor environment makes cancer cells more resistant to immunotherapy, according to a new study. Blocking that binding could improve responses to treatment.

Tracking human cancers in mice shows some unexpected cell changes that could undermine translational research.  

A career-altering experience as a cancer patient motivated one researcher to design more potent immunotherapies.

A guide to mRNA-based cancer vaccines and where they’re headed next